Market Analysis

Market Analysis


Dermatological conditions are one of the most common types of disorders worldwide, and approximately two-third of the world population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Scope


The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products. Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.



  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
  • Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.

Companies related to Dermatology:


  • Allergan Inc
  • AbbVie
  • Almirall, S.A
  • Bayer AG
  • Biofrontera AG
  • Derma Sciences
  • Galderma
  • GlaxoSmithKline (GSK)
  • Hill Dermaceuticals Inc
  • Johnson & Johnson
  • LEO Pharma
  • Merck & Co. Inc
  • Merz Pharma
  • Novartis Inc
  • Pfizer
  • Pierre Fabre
  • Stiefel Laboratories, Inc
  • Valeant Pharmaceuticals International Inc
  • Kythera Biopharmaceuticals Inc
  • Zeltiq Aesthetics Inc